← FDA DRUG APPROVALS

FDA ANDA · ANDA204661

OMEPRAZOLE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA204661
TYPE
ANDA
ORIGINAL APPROVAL
2017-06-13
LATEST ACTION
2023-07-18
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Discontinued, Prescription

Products

OMEPRAZOLEDiscontinued
OMEPRAZOLE 40MG · CAPSULE, DELAYED REL PELLETS · ORAL
OMEPRAZOLEPrescription
OMEPRAZOLE 20MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2023-07-18Labeling · Supplement 8 · standardAP
2022-03-04Labeling · Supplement 7 · standardAP
2018-06-07Labeling · Supplement 2 · standardAP
2017-06-13UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →